Literature DB >> 7650133

Tolerability of intramuscular injections of testosterone ester in oil vehicle.

M A Mackey1, A J Conway, D J Handelsman.   

Abstract

We undertook a prospective survey of the tolerability of deep i.m. injections of testosterone enanthate in a castor oil vehicle, the most widely used form of androgen replacement therapy. Over a period of 8 months, 26 men received 551 weekly injections into the gluteal, deltoid or thigh muscle and side-effects were recorded immediately and 1 week after each injection by the same nurse using a standardized questionnaire. Most injections caused no complaints [389/551, 70.6% (95% confidence interval 66.6-74.4%)] but minor local side-effects, mostly pain and bleeding, were common [162/551, 29.4% (25.6-33.4%)]; no serious side-effects were observed. Considering all side-effects, the gluteal site had fewer complaints and was less prone to bleeding but was painful more often than deltoid or thigh injection sites. The laterality of injection at any site had no significant effect on side-effects. The only systemic side-effect was episodes of sudden-onset, non-productive cough associated with faintness following eight injections [1.5% (0.6-2.9%)] which we speculate may have been due to pulmonary oil microembolism. We conclude that, when administered by an experienced nurse, deep i.m. injection of testosterone enanthate in a castor oil vehicle is generally safe and well tolerated but causes relatively frequent minor side-effects, including pain and bleeding. An improved depot form of testosterone would be highly desirable for androgen replacement therapy and hormonal male contraception.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7650133     DOI: 10.1093/oxfordjournals.humrep.a136051

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  10 in total

Review 1.  Testosterone hormone replacement therapy: state-of-the-art and emerging technologies.

Authors:  Marie-Laure Leichtnam; Hervé Rolland; Patrick Wüthrich; Richard H Guy
Journal:  Pharm Res       Date:  2006-06-09       Impact factor: 4.200

2.  An update on male hypogonadism therapy.

Authors:  Prasanth Surampudi; Ronald S Swerdloff; Christina Wang
Journal:  Expert Opin Pharmacother       Date:  2014-04-23       Impact factor: 3.889

3.  Therapy: Are long-acting intramuscular testosterone injections safe?

Authors:  Michael Zitzmann
Journal:  Nat Rev Urol       Date:  2015-04-07       Impact factor: 14.432

4.  Factors influencing time course of pain after depot oil intramuscular injection of testosterone undecanoate.

Authors:  Gideon Sartorius; Carolyn Fennell; Sasa Spasevska; Leo Turner; Ann J Conway; David J Handelsman
Journal:  Asian J Androl       Date:  2010-02-01       Impact factor: 3.285

Review 5.  Occurrence of pulmonary oil microembolism (POME) with intramuscular testosterone undecanoate injection: literature review.

Authors:  Jarren A Adam; Alexander W Pastuszak; Michael B Christensen; Rachel Spencer; Ashlynn Sandberg; James M Hotaling; Larry I Lipshultz
Journal:  Int J Impot Res       Date:  2022-05-24       Impact factor: 2.896

Review 6.  Androgen replacement therapy: present and future.

Authors:  Louis J G Gooren; Mathijs C M Bunck
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 7.  New long-acting androgens.

Authors:  Louis J Gooren
Journal:  World J Urol       Date:  2003-10-09       Impact factor: 4.226

8.  Anaphylaxis triggered by benzyl benzoate in a preparation of depot testosterone undecanoate.

Authors:  Gregory S Y Ong; Colin P Somerville; Timothy W Jones; John P Walsh
Journal:  Case Rep Med       Date:  2012-01-05

9.  Pharmacokinetic Profile of Subcutaneous Testosterone Enanthate Delivered via a Novel, Prefilled Single-Use Autoinjector: A Phase II Study.

Authors:  Jed Kaminetsky; Jonathan S Jaffe; Ronald S Swerdloff
Journal:  Sex Med       Date:  2015-09-17       Impact factor: 2.491

10.  Occurrence of Pulmonary Oil Microembolism After Testosterone Undecanoate Injection: A Postmarketing Safety Analysis.

Authors:  Alexander W Pastuszak; Yiqun Hu; Jeffrey D Freid
Journal:  Sex Med       Date:  2020-03-14       Impact factor: 2.491

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.